Services on Demand
Journal
Article
Indicators
- Cited by SciELO
Related links
- Similars in SciELO
Share
Acta Médica Peruana
On-line version ISSN 1728-5917
Abstract
ALDECOA, Franklin. Metastatic colorrectal cancer: overall survival rates with different therapy approaches in Lima. Acta méd. Peru [online]. 2019, vol.36, n.3, pp.195-201. ISSN 1728-5917.
Objectives: To assess overall survival rates of metastatic colorectal cancer in Lima, according to the therapy schedule used (independently of the K-ras gene mutational status), and to compare these results with those obtained in other similar studies elsewhere. Materials and Methods: This is a retrospective multicenter study. Clinical records of patients with metastatic colorectal cancer treated in specialized Lima hospitals within a time frame between January 2010 and December 2014 were analyzed. Out of 419 cases with a diagnosis of metastatic colorectal cancer, 320 (76.4%) complied with inclusion criteria and were considered for this study. Results: Mean age for participants was 63 years (range: 15 to 90 years). Survival 2-year and 5-year rates were 87.3% and 12.9% for those who underwent metastatic disease resection, and 39.6% and 9.1% for those patients who received chemotherapy (with or without biologics). Differences were statistically significant, favoring metastatic disease resection (p<0.001). Median overall survival rates were 18.1 months (95% CI: 16.5-19.7) for patients treated with chemotherapy and 24.2 months (95% CI: 18.1-30.3) for those who received monoclonal antibodies plus chemotherapy, but there were no significant differences between these groups. Conclusions: Survival rates found in the different groups included in this study, independently of the mutational status of the exon 2 of the K-ras gene, were well within the ranges that have been usually reported in the literature.
Keywords : Colorectal neoplasms; Chemotherapy, adjuvant; Neoplasm metastasis; Survival analysis.